{"id":"ypeg-rhg-csf","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Bone pain"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This conjugation increases the half-life of G-CSF, allowing for longer-lasting stimulation of white blood cell production. PEG-rhG-CSF is used to prevent infection in patients undergoing chemotherapy or bone marrow transplantation.","oneSentence":"PEG-rhG-CSF is a recombinant human granulocyte colony-stimulating factor (G-CSF) conjugated with polyethylene glycol (PEG), which helps stimulate the production of white blood cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:18.219Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of infection in patients undergoing chemotherapy or bone marrow transplantation"}]},"trialDetails":[{"nctId":"NCT06926751","phase":"PHASE2","title":"Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-04-07","conditions":"Solid Tumors, Children, Adolescent","enrollment":132},{"nctId":"NCT04466137","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2020-10-16","conditions":"Non-Myeloid Malignancy","enrollment":398},{"nctId":"NCT02005458","phase":"PHASE2","title":"Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2013-12","conditions":"Non Small Cell Lung Cancer, Breast Cancer","enrollment":80},{"nctId":"NCT01238562","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2010-04","conditions":"Chemotherapy Patients","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"YPEG-rhG-CSF","genericName":"YPEG-rhG-CSF","companyName":"Xiamen Amoytop Biotech Co., Ltd.","companyId":"xiamen-amoytop-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"YPEG-rhG-CSF is a protein-based intervention used to treat various conditions, including chemotherapy patients, non-myeloid malignancy, non-small cell lung cancer, breast cancer, and solid tumors. It is a modified form of recombinant human granulocyte colony-stimulating factor (rhG-CSF) conjugated with polyethylene glycol (PEG).","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}